EVE Evolva Holding SA

Evolva launches its Natural Nootkatone

Evolva Holding SA / Key word(s): Market launch
Evolva launches its Natural Nootkatone

14.12.2022 / 07:00 CET/CEST


Reinach, 14 December 2022 – Evolva (SIX: EVE) a pioneer in the field of natural molecules and industrial biotech, is lauching “Natural Nootkatone by Evolva”, a natural ingredient at the highest purity level now meeting all requirements to be qualified as natural also in the EU, in addition to the US. This broadens Evolva’s existing Nootkatone offering and opens up significant new addressable markets based on naturality and sustainability.
 

Nootkatone is an ingredient that is found naturally in grapefruits and other plants. Thanks to its citrusy, woody and fruity taste profile, it finds various applications in foods, beverages and fragrances. When extracted from the peel of the fruit, several hundred thousand grapefruits are required to yield one kilogram of Nootkatone. Thanks to its proprietary precision fermentation platform, Evolva can supply Nootkatone in large amounts in a highly sustainable, contaminant-free and cost-effective manner at highest purity levels of 85% and even 98%.

Already today, Evolva is one of three main players in the Nootkatone market. By further refining the production process, Natural Nootkatone by Evolva is now meeting all requirements to be qualified as natural also in the EU, in addition to the US. This broadens Evolva’s existing Nootkatone offering and significantly expands the addressable markets. Natural Nootkatone by Evolva is being launched with selected customers and will see a full market introduction in the first half of 2023.

Anne De Vos, Chief Commercial Officer of Evolva, comments: ”The launch of our new Natural Nootkatone capitalizes on a clear market demand. We enable our customers from the Flavors & Fragrances industry to build tomorrow’s sensoric experiences, while meeting growing consumers’ expectations for natural ingredients with a favorable environmental footprint”.

Christian Wichert, CEO of Evolva, adds: “Evolva is progressing well on the implementation of the strategic roadmap presented in August. With Natural Nootkatone by Evolva we broaden our product portfolio within one of our strategic pillars and aim to significantly increase our market share in the overall Nootkatone market over the coming years.”

 

As communicated on 6 October 2022, Evolva continues to enjoy good business momentum and is on track to reach its full-year 2022 targets. The company plans to release respective preliminary key figures for 2022 in January 2023 – ahead of the detailed full-year results release on 9 March 2023.


 

Important dates

09 March 2023 Full-year 2022 results

18 April 2023  Annual General Meeting

 

 

Contact

Doris Rudischhauser

Head of Investor Relations and Corporate Communications

8

 
 

About Natural Nootkatone

Nootkatone is an ingredient that is found naturally in grapefruit and certain other plants. It has the taste and smell of grapefruit with what is commonly referred to as a citrus, woody and fruity profile. This profile is quite unique and gives the ingredient some very specific applications in the Flavors & Fragrances industry. Evolva’s Natural Nootkatone that is produced via its natural precision fermentation process, rather than by extraction from the skin of grapefruits, can be produced in large amounts in a highly reproducible, contaminant-free, sustainable and cost-effective manner. At the highest purity levels  Natural Nootkatone by Evolva comes in liquid (Natural Nootkatone 85%) and crystal forms (Natural Nootkatone 98%) and is fully approved for use in both flavors and fragrances. This Nootkatone has a distinctive citrus and woody aroma, ideal for beverages. Moreover, it has citrus, grapefruit, woody and dry notes ideal for fine fragrances. It is perfectly line with current consumers’ expectations for clean and green products with a low environmental footprint.

 
 

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at and connect with us on .

For Evolva multimedia content, please visit: .

 
 

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.             
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.



End of Media Release


Language: English
Company: Evolva Holding SA
Duggingerstrasse 23
4153 Reinach
Switzerland
Phone: 0
Internet:
ISIN: CH0021218067
Valor: 2121806
Listed: SIX Swiss Exchange
EQS News ID: 1512321

 
End of News EQS News Service

1512321  14.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1512321&application_name=news&site_id=research_pool
EN
14/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evolva Holding SA

 PRESS RELEASE

Shareholders of Evolva Holding SA in liquidation approve BoD proposals...

Evolva Holding SA / Key word(s): AGMEGM Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected 12.04.2024 / 19:10 CET/CEST PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR   Shareholders of Evolva Holding SA in liquidation approve proposals put forward by the Board of Directors at Annual General Meeting; of the three agenda items put forward by Nice & Green, revocation of the liquidation and the delisting were also approved whereas introduc...

 PRESS RELEASE

Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG...

Evolva Holding SA / Key word(s): Takeover Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 28.12.2023 / 17:45 CET/CEST PRESS RELEASE   Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 Reinach, Switzerland, 28 December 2023 — Following the approval on 21 December 2023 by the shareholders of Evolva Holding AG (SIX: EVE) of the sale of Evolva AG to Danstar Ferment AG, a Swiss affiliate of Lallemand Inc., the parties have successfully closed the transaction on 28 December 2023. Evolva Holding S...

 PRESS RELEASE

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss sub...

Evolva Holding SA / Key word(s): AGMEGM Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting 21.12.2023 / 17:45 CET/CEST PRESS RELEASE   Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting Reinach, 21 December 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved all the proposals put forward by the Board of Directors at today’s extraordinary general meeting (EGM). The sharehol...

 PRESS RELEASE

Evolva and Breko broaden partnership by signing agreement for the excl...

Evolva Holding SA / Key word(s): Agreement Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam 14.11.2023 / 07:00 CET/CEST PRESS RELEASE   Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTMResveratrol in Germany, Austria, Thailand and Vietnam Reinach, 14 November 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and Breko GmbH, Bremen, Germany (“Breko”), a leading supplier of p...

 PRESS RELEASE

Evolva shareholders approve increase of the conditional capital and up...

Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 24.08.2023 / 20:00 CET/CEST PRESS RELEASE   Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 Reinach, 24 August 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved the proposals put forward by the Board of Direct...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch